Voclosporin Induces Systemic Lipidomic Alterations: Implications for Lupus Nephritis Remission

Lupus nephritis (LN) is a major cause of morbidity and mortality with a lifetime incidence of up to 60% in systemic lupus erythematosus (SLE).1 Cardiovascular diseases (CVD) are also the leading cause of death in patients with SLE.2 LN is an independent risk factor for CVD which increases the risk of CVD by two times as compared to SLE patients without LN.3 Goals of treatment in LN include preserving kidney function and reducing mortality, while minimizing treatment related adverse events and improving quality of life.